Dyskinesia - Pipeline Review, H2 2016

Dyskinesia - Pipeline Review, H2 2016


  • Products Id :- GMDHC8451IDB
  • |
  • Pages: 170
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dyskinesia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Dyskinesia - Pipeline Review, H2 2016', provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyskinesia

- The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects

- The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dyskinesia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Dyskinesia Overview 8

Therapeutics Development 9

Pipeline Products for Dyskinesia - Overview 9

Pipeline Products for Dyskinesia - Comparative Analysis 10

Dyskinesia - Therapeutics under Development by Companies 11

Dyskinesia - Therapeutics under Investigation by Universities/Institutes 14

Dyskinesia - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Dyskinesia - Products under Development by Companies 18

Dyskinesia - Products under Investigation by Universities/Institutes 21

Dyskinesia - Companies Involved in Therapeutics Development 22

Adamas Pharmaceuticals, Inc. 22

Addex Therapeutics Ltd 23

Advicenne 24

Astraea Therapeutics, LLC 25

Bionomics Limited 26

Catalyst Biosciences, Inc. 27

Catalyst Pharmaceuticals, Inc. 28

Clevexel Pharma SAS 29

Contera Pharma ApS 30

EpiVax, Inc. 31

Heptares Therapeutics Limited 32

Hua Medicine (Shanghai) Ltd. 33

Integrative Research Laboratories Sweden AB 34

Ipsen S.A. 35

Merz Pharma GmbH & Co. KgaA 36

MitoDys Therapeutics Limited 37

Neurim Pharmaceuticals Ltd 38

Neurocrine Biosciences, Inc. 39

Neurolixis Inc. 40

Osmotica Pharmaceutical Corp. 41

Otsuka Holdings Co., Ltd. 42

Phenomenome Discoveries, Inc. 43

Revance Therapeutics, Inc. 44

Sage Therapeutics, Inc. 45

SciFluor Life Sciences, LLC 46

SOM Innovation Biotech SL 47

Synchroneuron Inc. 48

Teva Pharmaceutical Industries Ltd. 49

Dyskinesia - Therapeutics Assessment 50

Assessment by Monotherapy Products 50

Assessment by Combination Products 51

Assessment by Target 52

Assessment by Mechanism of Action 55

Assessment by Route of Administration 58

Assessment by Molecule Type 60

Drug Profiles 62

(dextromethorphan + quinidine sulfate) - Drug Profile 62

A2M-13677 - Drug Profile 67

abobotulinumtoxin A - Drug Profile 68

acamprosate calcium SR - Drug Profile 72

amantadine hydrochloride ER - Drug Profile 74

amantadine hydrochloride ER - Drug Profile 80

AT-127 - Drug Profile 81

AT-326 - Drug Profile 82

AT-403 - Drug Profile 83

befiradol - Drug Profile 84

CPP-115 - Drug Profile 86

CVXL-0107 - Drug Profile 90

deutetrabenazine ER - Drug Profile 91

dipraglurant ER - Drug Profile 95

dipraglurant IR - Drug Profile 96

Drug for Dyskinesia - Drug Profile 100

HTL-14242 - Drug Profile 101

incobotulinumtoxin A - Drug Profile 102

IRL-790 - Drug Profile 105

JM-010 - Drug Profile 106

MLR-1019 - Drug Profile 108

NBI-640756 - Drug Profile 109

Neu-120 - Drug Profile 110

Neu-240 - Drug Profile 111

onabotulinumtoxinA - Drug Profile 112

PEUN-3 - Drug Profile 113

PPI-1011 - Drug Profile 114

remeglurant - Drug Profile 115

RT-002 - Drug Profile 116

SAGE-217 - Drug Profile 118

sepranolone - Drug Profile 120

SK-609 - Drug Profile 127

Small Molecule for Dyskinesia - Drug Profile 128

Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile 129

Small Molecules for Neurodegenerative Disease - Drug Profile 130

Small Molecules for Tardive Dyskinesia - Drug Profile 131

Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 132

Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 133

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 134

Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 135

Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 136

SOM-3355 - Drug Profile 137

TC-8831 - Drug Profile 138

tetrabenazine - Drug Profile 139

valbenazine tosylate - Drug Profile 140

Dyskinesia - Dormant Projects 146

Dyskinesia - Discontinued Products 149

Dyskinesia - Product Development Milestones 150

Featured News & Press Releases 150

Appendix 165

Methodology 165

Coverage 165

Secondary Research 165

Primary Research 165

Expert Panel Validation 165

Contact Us 165

Disclaimer 166

List of Figures

Number of Products under Development for Dyskinesia, H2 2016 13

Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Products, H2 2016 21

Assessment by Monotherapy Products, H2 2016 54

Number of Products by Top 10 Targets, H2 2016 56

Number of Products by Stage and Top 10 Targets, H2 2016 56

Number of Products by Top 10 Mechanism of Actions, H2 2016 59

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 59

Number of Products by Routes of Administration, H2 2016 62

Number of Products by Stage and Routes of Administration, H2 2016 62

Number of Products by Molecule Types, H2 2016 64

Number of Products by Stage and Molecule Types, H2 2016 64

List of Tables

Number of Products under Development for Dyskinesia, H2 2016 13

Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Development, H2 2016 21

Products under Development by Companies, H2 2016 22

Products under Development by Companies, H2 2016 (Contd..1) 23

Products under Development by Companies, H2 2016 (Contd..2) 24

Products under Investigation by Universities/Institutes, H2 2016 25

Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 26

Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2016 27

Dyskinesia - Pipeline by Advicenne, H2 2016 28

Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H2 2016 29

Dyskinesia - Pipeline by Bionomics Limited, H2 2016 30

Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H2 2016 31

Dyskinesia - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 32

Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2016 33

Dyskinesia - Pipeline by Contera Pharma ApS, H2 2016 34

Dyskinesia - Pipeline by EpiVax, Inc., H2 2016 35

Dyskinesia - Pipeline by Heptares Therapeutics Limited, H2 2016 36

Dyskinesia - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 37

Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 38

Dyskinesia - Pipeline by Ipsen S.A., H2 2016 39

Dyskinesia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 40

Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H2 2016 41

Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 42

Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2016 43

Dyskinesia - Pipeline by Neurolixis Inc., H2 2016 44

Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H2 2016 45

Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 46

Dyskinesia - Pipeline by Phenomenome Discoveries, Inc., H2 2016 47

Dyskinesia - Pipeline by Revance Therapeutics, Inc., H2 2016 48

Dyskinesia - Pipeline by Sage Therapeutics, Inc., H2 2016 49

Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H2 2016 50

Dyskinesia - Pipeline by SOM Innovation Biotech SL, H2 2016 51

Dyskinesia - Pipeline by Synchroneuron Inc., H2 2016 52

Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 53

Assessment by Monotherapy Products, H2 2016 54

Assessment by Combination Products, H2 2016 55

Number of Products by Stage and Target, H2 2016 57

Number of Products by Stage and Mechanism of Action, H2 2016 60

Number of Products by Stage and Route of Administration, H2 2016 63

Number of Products by Stage and Molecule Type, H2 2016 65

Dyskinesia - Dormant Projects, H2 2016 150

Dyskinesia - Dormant Projects (Contd..1), H2 2016 151

Dyskinesia - Dormant Projects (Contd..2), H2 2016 152

Dyskinesia - Discontinued Products, H2 2016 153

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adamas Pharmaceuticals, Inc.

Addex Therapeutics Ltd

Advicenne

Astraea Therapeutics, LLC

Bionomics Limited

Catalyst Biosciences, Inc.

Catalyst Pharmaceuticals, Inc.

Clevexel Pharma SAS

Contera Pharma ApS

EpiVax, Inc.

Heptares Therapeutics Limited

Hua Medicine (Shanghai) Ltd.

Integrative Research Laboratories Sweden AB

Ipsen S.A.

Merz Pharma GmbH & Co. KgaA

MitoDys Therapeutics Limited

Neurim Pharmaceuticals Ltd

Neurocrine Biosciences, Inc.

Neurolixis Inc.

Osmotica Pharmaceutical Corp.

Otsuka Holdings Co., Ltd.

Phenomenome Discoveries, Inc.

Revance Therapeutics, Inc.

Sage Therapeutics, Inc.

SciFluor Life Sciences, LLC

SOM Innovation Biotech SL

Synchroneuron Inc.

Teva Pharmaceutical Industries Ltd.

Dyskinesia Therapeutic Products under Development, Key Players in Dyskinesia Therapeutics, Dyskinesia Pipeline Overview, Dyskinesia Pipeline, Dyskinesia Pipeline Assessment

select a license

Single User License
USD 2000 INR 128700
Site License
USD 4000 INR 257400
Corporate User License
USD 6000 INR 386100

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com